The nation's bioscience industry continues to grow as states and regions vie to attract high-wage jobs, according to a study released on June 18, 2008, by Battelle (Columbus, OH) and the Biotechnology Industry Organization (BIO, Washington, DC).
The nation's bioscience industry continues to grow as states and regions vie to attract high-wage jobs, according to a study released on June 18, 2008, by Battelle (Columbus, OH) and the Biotechnology Industry Organization (BIO, Washington, DC).
The study, “Technology, Talent and Capital: State Bioscience Initiatives 2008,” presents data on national, state, and metropolitan bioscience employment and growth trends during 2001 to 2006. The study also examines a series of additional key performance metrics and describes state policies and programs designed to accelerate the growth of the biosciences. The report has been produced from the most current and comparable annual data available.
Total US employment in the biosciences reached 1.3 million in 2006, up from 1.2 million in 2004, led by strong growth in the research, testing, and medical laboratory subsector, which experienced a 17.8% increase in employment and a 32.7% increase in establishments between 2001 and 2006. Indirect and induced employment from the bioscience industry totals an additional 6.2 million jobs spread throughout the remainder of the economy.
Together, these direct, indirect, and induced jobs account for a total employment impact of 7.5 million jobs.
Following are some of the findings in the report:
In addition to employment, the report examines other indicators of the robustness of a state’s bioscience industry, including the level of bioscience R&D funding, venture capital investment, and patents. The highlights of additional key indicators include:
The study and individual profiles of the 50 states and Puerto Rico are available on the BIO website at http://www.bio.org/local/battelle2008.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.